Walleye Capital LLC Argenx Se Put Options Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $43,422 - $55,190	100 Added 14.29%	800 $433,000
Q2 2024 Aug 14, 2024	SELL	$356.01 - $451.55 $1.25 Million - $1.58 Million	-3,500 Reduced 83.33%	700 $301,000
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $571,120 - $661,264	1,600 Added 61.54%	4,200 $1.65 Million
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $508,365 - $759,015	1,500 Added 136.36%	2,600 $989,000
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $406,285 - $603,273	1,100 New	1,100 $540,000
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $1.67 Million - $2.02 Million	5,000 Added 217.39%	7,300 $2.72 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $786,991 - $925,313	2,300 New	2,300 $871,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.